LACTOLOGY FOUNDATION

Bromopride (ATC A03FA04) is a dopamine D2‑receptor antagonist prokinetic/antiemetic, closely related to metoclopramide, used mainly for nausea, vomiting and functional upper GI motility disorders, with limited but reassuring human data in pregnancy and essentially absent direct data in breastfeeding. Lactation risk is extrapolated from pharmacology and animal work, suggesting low expected milk transfer but theoretical risk of extrapyramidal effects and prolactin‑mediated changes in lactation, so cautious, short‑term use with infant monitoring is generally advised when clearly indicated.medpedia.framar+6

ATC Group and Members

Bromopride is classified in the WHO ATC system as A03FA04, within “Drugs for functional gastrointestinal disorders” (A03), subgroup “Propulsives” (A03F, A03FA). In this subgroup bromopride is the only substance officially listed under the specific code A03FA04, while related benzamide or prokinetic agents (e.g. metoclopramide A03FA01, cisapride A03FA02, domperidone A03FA03) are coded separately.atcddd.fhi+3

Pharmacological Class and Mechanism

Bromopride is a substituted benzamide and dopamine D2‑receptor antagonist with antiemetic and gastrointestinal prokinetic properties. It blocks D2 receptors in the chemoreceptor trigger zone and within the GI tract, enhancing gastric emptying, increasing upper GI motility and reducing gastroesophageal reflux; experimental work also suggests agonist activity at 5‑HT4 receptors in human atrial tissue, consistent with other benzamide prokinetics.wikipedia+6

Indications in General Use

Clinically, bromopride is indicated for the treatment of nausea and vomiting of various origins, including postoperative nausea and vomiting and nausea associated with gastrointestinal disorders. It is also used in gastroesophageal reflux disease and as a prokinetic to manage functional upper GI motility disorders, such as functional dyspepsia, gastric stasis and some biliary or colonic spastic conditions, and may be used as preparation for endoscopy or radiologic GI procedures.drugbank+4

Adverse Effects and Contraindications

The most common adverse effects reported with bromopride are somnolence and fatigue, reflecting central dopaminergic blockade. As with other benzamide D2 antagonists, extrapyramidal reactions (acute dystonia, akathisia, parkinsonism) can occur, and bromopride may raise serum prolactin levels, potentially leading to galactorrhea or menstrual disturbances in non‑lactating women; hypersensitivity to bromopride or excipients is a formal contraindication.alfa-chemistry+3

Core Lactation Pharmacokinetic Considerations

No human milk‑level studies for bromopride were identified, so risk assessment must be based on general principles of drug entry into human milk and on its pharmacology. The extent of transfer into milk is influenced by maternal plasma concentration, molecular size, lipid solubility, protein binding, oral bioavailability in the infant and elimination half‑life, with higher maternal levels and low protein binding generally increasing milk penetration.pubmed.ncbi.nlm.nih+2

Because bromopride is a systemically active, CNS‑penetrant dopamine antagonist, its chemistry would not preclude milk transfer, but substantial protein binding and preference for short‑term, intermittent dosing would tend to limit infant exposure in typical clinical use. Choosing the minimum effective dose, avoiding prolonged courses, and timing feeds to avoid maternal peak levels (usually by waiting 2–3 hours after dosing before nursing) can further reduce infant exposure.infantrisk+1

Experimental and Animal Data Relevant to Lactation

A perinatal rat study evaluating bromopride exposure during pregnancy and lactation found that offspring of mothers treated during lactation demonstrated increased general activity and higher apomorphine‑induced stereotypy scores shortly after weaning. These effects were not seen in pups exposed only in utero and were less evident when exposure included both pregnancy and lactation, suggesting that bromopride can interact with developing dopaminergic pathways during sensitive postnatal periods in rodents.pubmed.ncbi.nlm.nih

Although extrapolation from animals to humans is limited, these findings support a cautious approach in breastfeeding, particularly regarding long‑term or high‑dose maternal therapy, and underline the theoretical risk of subtle neurobehavioral effects in the infant.infantrisk+1

Potential Effects on the Breastfed Infant

Given its D2‑blocking and CNS‑active profile, the main theoretical infant risks from bromopride exposure via breast milk are neurologic and gastrointestinal. Possible clinical manifestations include sedation, irritability, feeding difficulties, abnormal movements or extrapyramidal symptoms, and changes in GI motility such as diarrhea or colic‑like symptoms.wikipedia+3

Because bromopride is pharmacologically similar to metoclopramide, which has occasionally caused extrapyramidal reactions in children at therapeutic doses, infants should be monitored for acute dystonia (e.g. abnormal posturing, oculogyric crisis), unusual restlessness, or persistent vomiting if maternal bromopride is used during lactation. Parents and clinicians should also observe for poor weight gain and altered sleep‑wake patterns, which may indicate clinically relevant exposure.drugbank+3

Potential Effects on Lactation and Prolactin

Dopamine antagonists such as bromopride can increase prolactin by disinhibiting pituitary lactotrophs, and bromopride has been noted to elevate prolactin levels and occasionally induce galactorrhea in non‑lactating women. In a breastfeeding woman with established lactation, such prolactin elevation may have little clinical impact or could modestly increase milk production; in early postpartum, it might theoretically support lactogenesis if not excessive.alfa-chemistry+3

Conversely, uncontrolled prolactin elevation outside the normal physiologic range is not desirable and may contribute to breast discomfort or menstrual irregularities, so bromopride should not be used solely as a galactagogue given its CNS and extrapyramidal risk profile. General reviews of lactation pharmacology emphasize preferring drugs with shorter half‑life and good safety data in nursing mothers when medication is optional, reserving agents like bromopride for situations where they are clearly essential and no safer alternatives exist.gpnotebook+4

Clinical Risk Assessment in Breastfeeding

In the absence of direct human lactation data, bromopride during breastfeeding is best considered a drug for cautious use, reserved for mothers with significant nausea, vomiting or functional GI disorders where other, better‑characterized options are unsuitable. Short‑term use at the lowest effective dose, particularly in healthy term infants, is unlikely to result in clinically significant exposure, provided there is appropriate monitoring and avoidance of concurrent dopamine antagonists in the infant.gpnotebook+3

Higher‑risk contexts include premature or medically fragile infants, prolonged maternal therapy, high doses or polypharmacy with other CNS‑active agents, in which case alternative antiemetics or non‑pharmacologic strategies should be strongly considered. Where bromopride remains clinically necessary under such conditions, more intensive infant follow‑up (growth, neurologic status and feeding behavior) is advisable, and temporary interruption of breastfeeding may be discussed in extreme cases.pubmed.ncbi.nlm.nih+2

Practical Recommendations for Healthcare Professionals

When prescribing bromopride (A03FA04) to breastfeeding women, clinicians should first evaluate whether a safer antiemetic or prokinetic with established lactation data can be substituted. If bromopride is selected, recommended precautions include limiting duration, using the minimum effective dose, timing breastfeeding to avoid maternal peak levels, and advising the mother on specific infant signs that should trigger prompt medical review.drugbank+2

Documentation should clearly record the indication, the assessment that benefits outweigh theoretical infant risks, and the planned monitoring strategy, aligning with general WHO‑style classifications in which compatible drugs at usual dosage are preferred and higher‑risk agents are reserved for compelling indications. Collaboration between prescriber, pharmacist and lactation‑knowledgeable professionals can help individualize decisions, especially in complex maternal or infant comorbidities.gpnotebook+1